LEADER 01854nam  2200385   450 
001 9910688169403321
005 20230626222146.0
024 7 $a10.5772/intechopen.95200
035   $a(CKB)5850000000050213
035   $a(NjHacI)995850000000050213
035   $a(EXLCZ)995850000000050213
100   $a20230626d2022      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aLeishmaniasis $eGeneral Aspects of a Stigmatized Disease /$fLeonardo de Azevedo Calderon, editor
210  1$aLondon :$cIntechOpen,$d2022.
215   $a1 online resource (256 pages)
311   $a1-83968-092-X 
330   $aLeishmaniasis is a major global health challenge, affecting approximately 12 million of the poorest people in 100 countries. It is a deforming and fatal disease in the visceral form. Therapies for leishmaniasis are numerically restricted, basically consisting of the administration of miltefosine, pentavalent antimonials, amphotericin B, or pentamidine. This is an important vulnerability against therapy efficiency that must be overcome by the scientific community. This book discusses important aspects of the disease, such as treatment, epidemiology, and molecular and cell biology. The information contained herein is important for young researchers as they seek to develop safe and effective treatments for this neglected tropical disease.
517   $aLeishmaniasis 
606   $aLeishmaniasis
606   $aLeishmaniasis, Mucocutaneous
615  0$aLeishmaniasis.
615  0$aLeishmaniasis, Mucocutaneous.
676   $a616.9364
702   $aCalderon$b Leonardo de Azevedo
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688169403321
996   $aLeishmaniasis$92953485
997   $aUNINA